Introduction {#s1}
============

Heart failure is a clinical syndrome often coupled to impaired cardiac contractility \[[@b1]\]. While several pharmacological and nonpharmacological interventions have been shown to improve outcomes in patients with heart failure (e.g., angiotensin-converting enzyme inhibitors, beta-blockers, aldosterone antagonists, coronary revascularization, biventricular pacing \[[@b2]\]), global rates of morbidity and mortality remain high \[[@b3], [@b4]\]. Inotropes, such as dobutamine, dopamine, and milrinone, increase cardiac contractility by increasing cardiac myocyte intracellular calcium, but these intracellular calcium increases have been associated with important liabilities (e.g., proarrhythmia) that limit their utility \[[@b5]\].

Omecamtiv mecarbil is a small molecule that directly activates cardiac myosin. It binds with high selectivity to cardiac myosin's enzymatic domain, increasing the rate of adenosine triphosphatase turnover and accelerating the transition of cardiac myosin into the force-generating state \[[@b6]\] without affecting calcium homeostasis. Consequently, more force-generating myosin heads interact with actin filaments, increasing contractility. In preclinical models, omecamtiv mecarbil has been shown to simultaneously improve myocardial efficiency and function \[[@b7]\], and clinical studies have added to these results. In healthy volunteers, a 6-hour infusion of omecamtiv mecarbil at dosing rates from 0.005 to 1.00 mg/kg/h produced linear, dose-independent pharmacokinetics \[[@b8]\] and a maximum plasma concentration (C~max~; 9 -- 1,203 ng/mL) that was proportional to the dose administered. Pharmacokinetics were similar in patients with heart failure \[[@b9]\].

The plasma protein binding of omecamtiv mecarbil in humans is \~ 82%, and it is mainly metabolized by a decarbamylation pathway, with modest metabolism, by CYP3A4 and CYP2D6. After a single dose \~ 8% of the intact parent compound can be recovered in urine collected up to 336 hours postdose, indicating extensive metabolism. Systemic clearance ranges from 132 to 207 mL/h/kg, terminal half-life from 17 to 21 hours, and apparent volumes of distribution from 3.7 to 5.2 L/kg, consistent with extensive extravascular distribution \[[@b8]\].

Omecamtiv mecarbil's increase in cardiac contractility is tightly coupled to the resulting increase in the systolic ejection time. Evidence of intolerance can appear at plasma concentrations exceeding the maximum effects on cardiac contractility, presumably due to excessive prolongation of the systolic ejection time, which may result in myocardial ischemia \[[@b9]\].

Oral omecamtiv mecarbil is known to be highly available (\> 90%) and rapidly absorbed (time to C~max~ \[t~max~\], 0.5 -- 1.0 hours). Given that intolerance is produced by excessive omecamtiv mecarbil plasma concentrations, modified-release (MR) formulations were developed with the goal of preserving overall bioavailability while lowering C~max~ and the peak-to-trough fluctuation at steady state. This phase 1 clinical trial was designed to compare the relative bioavailability of a single 25-mg dose of five omecamtiv mecarbil MR formulations with that of the reference immediate-release (IR) matrix formulation. The effect of food on the pharmacokinetics and tolerability were also evaluated.

Methods {#s2}
=======

Design {#sub-s1}
------

This was a phase 1, randomized, open-label, 4-way crossover, incomplete block-design study conducted in healthy subjects at 1 site. Using a computer-generated randomization schedule, subjects were randomized to 1 of 30 treatment sequences, each containing 4 treatment periods; 7 days for the first 3 and 5 days for the last treatment period. Treatments were separated by a 7-day interval to allow time for wash-out, for a total study duration of \~ 28 days ([Table 1](#Table1){ref-type="table"}) ([Figure 1](#Figure1){ref-type="fig"}). Each treatment sequence was assigned to 2 subjects and included 2 of the 6 formulations administered in a fasting or fed state. The protocol and informed consent form were approved by the site's institutional review board and all subjects provided written informed consent. Subjects who withdrew from the study before receiving omecamtiv mecarbil or for reasons other than adverse events were replaced with another subject who would receive the same randomized treatment sequence.

Pharmacokinetic sampling and liquid chromatography/tandem mass spectrometry (LC-MS/MS) assay {#sub-s2}
--------------------------------------------------------------------------------------------

Blood samples for the pharmacokinetic analysis were collected on day 1 predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, and 120 hours postdose in each period using K3-EDTA collection tubes. Plasma concentrations of omecamtiv mecarbil and its metabolites M3 and M4 were extracted from 0.25 mL of human plasma aliquots using a validated solid phase extraction method and determined by LC-MS/MS with multiple reaction monitoring TurboIonSpray ionization in the positive ion mode (Worldwide Clinical Trials, Austin, TX, USA). The assay had a lower limit of quantitation of 1.00 ng/mL for omecamtiv mecarbil and 0.500 ng/mL for M3 and M4. Samples were separated on a Phenomenex, Kinetex PFP, 2.6 micron, 3.0 × 30 mm analytical column, with gradient mobile phases of ammonium acetate solution and methanol, and methanol alone. Sample concentrations were determined from weighted linear regressions of peak area ratios (peak areas of omecamtiv mecarbil, M3, M4/corresponding stable isotope labeled internal standards) vs. nominal concentrations of the calibration curve standards. Accepted runs met routine acceptance criteria of ± 15% (± 20% at the lower limits of quantitation) for accuracy of the calibration standards and quality control samples.

Pharmacokinetic analysis {#sub-s3}
------------------------

The plasma concentration-time data for omecamtiv mecarbil, M3, and M4 were analyzed by noncompartmental methods using WinNonlin Enterprise (version 5.1.1; Pharsight Corporation, Mountain View, CA, USA). Actual dosing and sample collection times were used in this analysis. Plasma concentrations below the lower limit of quantification of 1.0 ng/mL for omecamtiv mecarbil and 0.5 ng/mL for M3 and M4 were set to zero for the data analysis of all analytes.

The pharmacokinetic parameters assessed were plasma concentration-time curve (area under the curve (AUC)) to time of last measureable concentration (AUC~last~), AUC to infinity (AUC~∞;~ calculated using the linear trapezoidal linear interpolation method), C~max~, t~max~, terminal elimination half-life associated with λ~z~ (t~1/2,z~), apparent plasma clearance (CL/F), the ratios of AUC~last~ of M3 and M4 to omecamtiv mecarbil, and the ratios of M3 and M4 AUC to the combined AUCs of all analytes (omecamtiv mecarbil, M3, M4 using ng×h/mL). The pharmacokinetic parameters of omecamtiv mecarbil, M3, and M4 were adjusted for each formulation by using their respective potency values where possible: IR = 0.979; MRT-F~1~ = 0.999; MRT-F~2~ = 0.995; MP = 0.984; SCT-F~1~ = 0.914; SCT-F~2~ = 0.910.

Safety and other assessments {#sub-s4}
----------------------------

Treatment-emergent adverse events from the initial dose to the end-of-study were evaluated at the same time points within each treatment period. Adverse events were assigned to the most-recently dosed treatment period before the event occurred and were classified according to Medical Dictionary for Regulatory Activities (version 15.0). Subject incidence of adverse events was tabulated for each individual treatment and aggregated across the fasting and fed states for each formulation, and across the formulations for each condition (treatment-emergent adverse events, fatal adverse events, serious adverse events, treatment-related adverse events, treatment-related serious adverse events, and withdrawal of omecamtiv mecarbil due to adverse events). All on-study electrocardiogram (ECG) and individual vital signs, chemistry (including troponin I), hematology, and urinalysis data were assessed.

Statistical analyses {#sub-s5}
--------------------

To assess relative bioavailability of each MR vs. the IR formulation, natural log-transformed AUC~∞~, AUC~last~, and C~max~ were analyzed separately using a mixed-effect model, with treatment, study period, and sequence as fixed effects, and subject within each sequence as a random effect. Relative bioavailability was analyzed on pharmacokinetic data from all study periods, with the IR formulation as the reference and the MR formulations as the test treatments. To assess the effect of food on the selected MR formulation, natural log transformed AUC~∞~, AUC~last~, and C~max~ were analyzed separately using a mixed-effect model, with fasting state as the fixed effect and subject as the random effect. Statistical evaluations were conducted using SAS Software and summary statistics, adjusted parameters, and ratio values were generated using WinNonlin Enterprise (Pharsight Inc., Mountain View, CA, USA) or Microsoft Excel software. Adverse events were described using descriptive statistics. Graphs were prepared using SigmaPlot (version 11.0), (Systat Software Inc., San Jose, CA, USA).

Materials {#sub-s6}
---------

The 25-mg omecamtiv mecarbil formulations included the IR, two MR matrix tablets (MRT-F~1~, MRT-F~2~), an MR multiparticulate capsule (MP), and 2 MR swellable core tablets (SCT-F~1~, SCT-F~2~) ([Table 2](#Table2){ref-type="table"}) ([Figure 2](#Figure2){ref-type="fig"}). All two formulations were administered as a single dose containing 25 mg of omecamtiv mecarbil.

Subjects {#sub-s7}
--------

Eligible subjects were healthy males and females between 18 and 50 years with no history or evidence of clinically-relevant medical disorders, as judged by the investigator and determined by a physical examination, laboratory tests, and a 12-lead ECG. Women were without reproductive potential, and men agreed to practice highly effective methods of birth control for the duration of the study and 11 weeks after receiving the last dose of omecamtiv mecarbil.

Exclusion criteria included a history of esophageal, gastric, or duodenal ulceration, or bowel disease; gastrointestinal surgery; or any type of malignancy within 5 years. Subjects were also excluded if they tested positive for human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C antibodies; or had troponin I above the upper limit of normal at screening or on the day before dosing, or an estimated glomerular filtration rate \< 80 mL/min/1.73^2^ within the screening period or on the day before dosing. Additional exclusion criteria included nicotine use; a substance abuse disorder within 1 year; treatment with agents known to affect drug metabolism, herbal medicines within 30 days, or certain over-the-counter medications; or previous exposure to omecamtiv mecarbil. Women who were breastfeeding and men with pregnant partners were also excluded.

Results {#s3}
=======

Subjects {#sub-s8}
--------

A total of 65 subjects received at least 1 dose of omecamtiv mecarbil; 5 were replacement subjects. A majority were white (72%) and male (85%), with a mean age of 33 years ([Table 3](#Table3){ref-type="table"}). Six (9%) subjects discontinued the study: 2 (3%) due to an adverse event, 1 (2%) due to noncompliance, 1 (2%) due to ineligibility, and 2 (3%) due to withdrawal of full consent. The pharmacokinetics of omecamtiv mecarbil was assessed in 62 subjects in the fasting and in 63 subjects in the fed state.

Pharmacokinetic analysis of omecamtiv mecarbil {#sub-s9}
----------------------------------------------

The mean maximum concentration was higher for the IR (C~max~ = 262 ng/mL) vs. the MR formulations, with SCT-F~1~ being the lowest (34 ng/mL) and MRT-F~2~ being the highest (78 ng/mL). Absorption was gradual for different MR formulations, with median t~max~ of 3 and 2 hours for MRT-F~1~ and MRT-F~2~, respectively; 4 hours for MP; and 10 and 6 hours for SCT-F~1~ and SCT-F~2~, respectively, compared with 0.5 hours for IR ([Table 4](#Table4){ref-type="table"}) ([Figure 3](#Figure3){ref-type="fig"}). The observed absorption was variable, yet slower (prolonged t~max~ for all MR formulations); with marginally longer median t~max~ for SCT-F~1~ and SCT-F~2~ (p = 0.046 each). The mean relative bioavailability for 3 of the MR formulations was high vs. IR: MRT-F~1~, 79%; MRT-F~2~, 87%; SCT-F~2~, 82%. The relative bioavailability was in the medium-to-low range for MP (64%) and SCT-F~1~ (58%) ([Table 4](#Table4){ref-type="table"}). There were no notable differences in half-life between the formulations (19 -- 21 hours) ([Table 4](#Table4){ref-type="table"}).

As with the fasting state, in the fed state, the concentrations of omecamtiv mecarbil increased gradually with lower C~max~ values for all MR formulations vs. the IR formulation (C~max~ = 144 ng/mL for IR vs. 50 -- 90 ng/mL for MR) ([Table 5](#Table5){ref-type="table"}) ([Figure 3](#Figure3){ref-type="fig"}). Half-life was comparable for all MR formulations, ranging from 18 to 21 hours.

Food effect {#sub-s10}
-----------

Omecamtiv mecarbil absorption was delayed in the fed state, with a longer t~max~ for IR, MRT-F~1~, MRT-F~2~, and MP formulations. For MRT-F~1~, MRT-F~2~, and MP formulations, t~max~ was doubled (3 vs. 6 hours (p = 0.0184), 2 vs. 4 hours (p = 0.0116), and 4 vs. 8 hours (p = 0.0002), respectively); there was no food effect on t~max~ for the SCT formulations (SCT-F~1~, 10 vs. 10 hours (p = 0.0522); SCT-F~2~, 6 vs. 6 hours (p = 0.3173) ([Table 6](#Table6){ref-type="table"}).

In the fed state, C~max~ was blunted by \~ 40% (90% confidence intervals (CI) 0.5, 0.6) and 20% (90% CI = 0.8, 0.9) for the IR and MP formulations, respectively. However, food had no effect on the total exposure (AUC~∞~) of any of the formulations, with 90% CIs contained within 80 -- 125%. For MRT-F~1~, food marginally increased C~max~ (20%; 90% CI = 1.1, 1.3) and AUC~∞~ (20%; 90% CI = 1.1, 1.3). Similar marginal increases were seen in the fed state for the MRT-F~2~ and SCT-F~2~ formulations with C~max~ (\< 30%; 90% CI = 1.0, 1.3 and 1.2, 1.5, respectively) and AUC~∞~ (\< 20%; 90% CI = 1.0, 1.2 and 1.0, 1.1, respectively). For the SCT-F~1~ formulation in the fed state, there was an increase in C~max~ (50%; 90% CI = 1.4, 1.7) and AUC~∞~ (30%; 90% CI = 1.2, 1.4).

Metabolite M3 and M4 exposure {#sub-s11}
-----------------------------

Following administration of the IR and MR formulations and similar to omecamtiv mecarbil, the concentrations of the circulating metabolites M3 and M4 gradually increased, but with a time-lag in the formation of the metabolites as confirmed by higher t~max~ values ([Table 4](#Table4){ref-type="table"}). The mean ratio of M3 : parent was \~ 9 -- 10% following administration of all 6 formulations, suggesting that formulation type did not affect total exposure of M3. Food also did not impact either peak or total exposure ([Table 5](#Table5){ref-type="table"}) ([Figure 4](#Figure4){ref-type="fig"}). Similarly, the mean ratio of M4 : parent was \~ 2 -- 3% following administration of all six formulations, suggesting that formulation type did not affect the total exposure of M4, with no effect of food on peak or total exposure ([Table 5](#Table5){ref-type="table"}) ([Figure 5](#Figure5){ref-type="fig"}).

Safety and tolerability {#sub-s12}
-----------------------

Adverse events were reported in 31% and 22% of subjects in the fasting and fed states, respectively. The most common adverse events (≥ 2 subjects) were headache (11%) and vomiting (5%) in the fasting state and headache (10%), contact dermatitis (3%), and upper respiratory tract infection (3%) in the fed state. There were no deaths or serious adverse events ([Table 7](#Table7){ref-type="table"}).

Two subjects discontinued the study due to an adverse event: 1 due to a urinary tract infection and 1 due to ventricular extrasystoles. In the subject with ventricular extrasystoles, the event was a telemetry finding that occurred 7 days after the last dose of the IR formulation. The subject did not experience symptoms or complaints, and 3 ECGs (2 on the same day, 1 on the 4^th^ day) did not show any changes suggestive of myocardial ischemia. The subject later had an ECG Holter, which was interpreted as normal. Troponin I at each time point was below the limit of quantification (\< 0.030 ng/mL). Clinical laboratory evaluation showed no notable differences across formulations and no notable difference between the fasting and fed states.

Six subjects with normal creatine kinase (CK) at baseline developed levels 5 -- 10 times the upper limit of normal during the study. One experienced muscle trauma the day prior to the blood draw, and the CK increase was reported as a treatment-emergent adverse event; all but 1 subject had a history of physical activity. These elevations were transient, resolved spontaneously, and did not lead to study discontinuation for 5 subjects. No other laboratory values were reported as an adverse event. Three subjects had troponin I levels within the suspicious range (0.05 -- 0.5 ng/mL), but below the range consistent with myocardial injury (\> 0.5 ng/mL). Two occurred 6 days after drug administration, and the subjects remained asymptomatic; 1subject was coincident with a markedly elevated CK above 10 times the upper limit of normal in the context of suspected intense exercise. No clinically significant ECG changes were noted, and none of these biomarker increases were reported as treatment-emergent adverse events.

Discussion {#s4}
==========

Because an increased risk of myocardial ischemia or infarction observed with high omecamtiv mecarbil concentrations is most likely due to an excessive pharmacological effect \[[@b9]\], 5 different MR formulations of omecamtiv mecarbil were developed with an aim of decreasing the C~max~ and peak-to-trough fluctuation, while minimally impacting total exposure. This phase 1 clinical study was designed to compare the relative bioavailability of these MR formulations with that of the reference IR formulation following administration of a single 25-mg dose and to evaluate the effect of food.

The five formulations evaluated in this study were two matrix tablet platforms with slower (MRT-F~1~, time to release 80% of omecamtiv mecarbil (T~80~) = 10 -- 12 hours) and faster release rates (MRT-F~2~ T~80~ = 6 -- 8 hours), one multiparticulate capsule with a faster release rate (MP T~80~ = 4 -- 6 hours), and two osmotic pump platforms with slower (SCT-F~1~, T~80~ = 8 -- 12 hours) and faster release rates (SCT-F~2~ T~80~ = 4 -- 6 hours). Compared with IR, none of the MR formulations showed any evidence of dose dumping, meeting one of the most important characteristics of an ideal MR formulation, with t~max~ values ranging from 2 to 10 hours. All MR formulations significantly reduced C~max~ by ≥ 70% and prolonged absorption in general. Of the MR formulations, MRT-F~1~, MRT-F~2~, and SCT-F~2~ had high relative bioavailability (\> 75%); MP and SCT-F~1~ had lower relative bioavailability (\< 65%). These data suggest that MRT-F~1~, MRT-F~2~, and SCT-F~2~ would achieve relatively similar total exposure as IR with lower peak exposure for a given dose.

The food effect did not differentiate between the different MR formulations; however, in the fed state, there was a trend toward increasing AUC and C~max~ for all MR formulations except MP, which had a decrease in overall AUC and C~max~ ([Table 6](#Table6){ref-type="table"}). Interestingly, the overall observed variability (% coefficient of variation for AUC~∞~ and C~max~) was reduced in the fed state for each of the formulations ([Tables 4](#Table4){ref-type="table"}, [Table 5](#Table5){ref-type="table"}). For the SCT-F~1~ formulation, food had a slightly greater effect on omecamtiv mecarbil pharmacokinetics vs. the other formulations; however, for the others the absolute change in AUC and C~max~ was \< 30%. With the IR formulation, food statistically significantly reduced omecamtiv mecarbil's C~max~, but had little effect on AUC and C~max~. The reason for this is not entirely understood, but it may be attributed to the slowing of dissolution as food tends to increase the pH of the stomach. An IR formulation is likely more susceptible to pH changes by its inherent fast-disintegrating properties, rapidly exposing the drug particles to the surrounding environment. Omecamtiv mecarbil is a biopharmaceutics classification system class 2 molecule; hence, a modifying effect of food was not unexpected, and the effect of food on omecamtiv mecarbil's pharmacokinetics following MR formulations administration was modest and not considered clinically meaningful. However, as food appeared to reduce variability, further analyses to evaluate the value of dosing with food would be informative.

The potency of omecamtiv mecarbil was modestly lower than the nominal intended dose of 25 mg for all formulations: in the SCT formulations, the intended potency was as low as \~ 91% due to drug substance being lost during the compression process. A secondary analysis using the potency-corrected AUC and C~max~ values showed mostly similar results and no meaningful effect on the relative bioavailability. Finally, the noncompartmental analysis-based t~1/2,z~ was similar for all formulations, with an overall mean range of 18 -- 21 hours in both the fasting and fed states, consistent with earlier omecamtiv mecarbil studies \[[@b8]\].

The pharmacokinetics of the metabolites M3 and M4 were unremarkable, and the conversion of omecamtiv mecarbil to M3 and M4 was similar for the different formulations. The ratio of M3 to parent (\~ 11%) and total (9%) was consistent across the formulations. The ratio of M4 to parent or total was \~ 2 -- 3% and was also consistent across the formulations, indicating that metabolic activity was not dependent on the rate of input of the drug to the system.

Single oral 25-mg doses of the MR formulations of omecamtiv mecarbil were generally well-tolerated, with no serious adverse events. In the 2 subjects who discontinued the study because of an adverse event, neither event appeared to have a causal relationship with omecamtiv mecarbil. Both events (urinary tract infection and ventricular extrasystoles) occurred 6 and 7 days after the last dose of the IR formulation, after more than 5 half-lives of the parent drug; none of the circulating metabolites had a slower elimination that could have been the probable cause of these adverse events. In the 6 subjects with elevations in CK, the disproportionate elevations over CK-MB were consistent with a skeletal muscle etiology. Elevations in CK are not uncommon in young men, the primary demographic in this study. Two additional subjects had modestly elevated asymptomatic troponin values; all 3 subjects had normal intervening cardiac troponins 24 hours following drug administration and prior to the observed elevated troponin values.

Conclusions {#s5}
===========

This study evaluated the pharmacokinetics and bioavailability of omecamtiv mecarbil MR formulations relative to the IR formulation in both fasting and fed states. Compared with the IR formulation, the relative bioavailability was generally high (\> 75%) for MRT-F~1~, MRT-F~2~, and SCT-F~2~, and lower for the SCT-F~1~ and MP formulations. Food had a minimal effect on the pharmacokinetics of these formulations, although it reduced overall variability. Based on these data, MRT-F~1~, MRT-F~2~, and SCT-F~2~ appear to have the desired characteristics of an MR formulation, and, as a result, were advanced for further study in patients with heart failure.
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Table 1.The 30 possible treatment sequences in which subjects received a single 25-mg dose of omecamtiv mercarbil.SequencePeriod 1 (days 1 -- 6)Period 2 (days 7 -- 13)Period 3 (days 14 -- 20)Period 4 (days 21 -- 26)1IR fastingMRT-F~1~ fastingMRT-F~1~ fedIR fed2MRT-F~2~ fastingIR fastingIR fedMRT-F~2~ fed3IR fastingMP fastingMP fedIR fed4SCT-F~1~fastingIR fastingIR fedSCT-F~1~fed5IR fastingSCT-F~2~fastingSCT-F~2~ fedIR fed6MRT-F~1~ fastingMRT-F~2~ fastingMRT-F~2~ fedMRT-F~1~ fed7MP fastingMRT-F~1~ fastingMRT-F~1~ fedMP fed8MRT-F~1~ fastingSCT-F~1~fastingSCT-F~1~fedMRT-F~1~ fed9SCT-F~2~fastingMRT-F~1~ fastingMRT-F~1~ fedSCT-F~2~fed10MRT-F~2~ fastingMP fastingMP fedMRT-F~2~ fed11SCT-F~1~fastingMRT-F~2~ fastingMRT-F~2~ fedSCT-F~1~fed12MRT-F~2~ fastingSCT-F~2~fastingSCT-F~2~fedMRT-F~2~ fed13MP fastingSCT-F~1~fastingSCT-F~1~fedMP fed14SCT-F~2~fastingMP fastingMP fedSCT-F~2~ fed15SCT-F~1~fastingSCT-F~2~fastingSCT-F~2~fedSCT-F~1~fed16MRT-F~1~ fedIR fedIR fastingMRT-F~1~ fasting17IR fedMRT-F~2~ fedMRT-F~2~ fastingIR fasting18MP fedIR fedIR fastingMP fasting19IR fedSCT-F~1~fedSCT-F~1~fastingIR fasting20SCT-F~2~fedIR fedIR fastingSCT-F~2~fasting21MRT-F~2~ fedMRT-F~1~ fedMRT-F~1~ fastingMRT-F~2~ fasting22MRT-F~1~ fedMP fedMP fastingMRT-F~1~ fasting23SCT-F~1~fedMRT-F~1~ fedMRT-F~1~ fastingSCT-F~1~fasting24MRT-F~1~ fedSCT-F~2~fedSCT-F~2~fastingMRT-F~1~ fasting25MP fedMRT-F~2~ fedMRT-F~2~ fastingMP fasting26MRT-F~2~ fedSCT-F~1~fedSCT-F~1~fastingMRT-F~2~ fasting27SCT-F~2~fedMRT-F~2~ fedMRT-F~2~ fastingSCT-F~2~fasting28SCT-F~1~fedMP fedMP fastingSCT-F~1~fasting29MP fedSCT-F~2~fedSCT-F~2~fastingMP fasting30SCT-F~2~fedSCT-F~1~fedSCT-F~1~fastingSCT-F~2~fasting[^1]

![Study design. In the fasting state, subjects received omecamtiv mecarbil after an overnight fast of ≥ 10 hours; in the fed state, subjects consumed a high-fat breakfast after an overnight fast ≥ 10 hours. IR = immediate release; MP = multiparticulate capsule; MRT-F = matrix tablet; SCT-F = swellable core tablet.](intjclinpharmacol-54-217-01){#Figure1}

Table 2.Formulation characteristics.FormulationDescriptionImmediate-release (IR) tabletsManufactured via a conventional high-shear wet-granulation processMatrix tablets (MRT-F~1~, MRT-F~2~)Based on hydrophilic polymer matrix systems\
Release rate is controlled by the polymer concentration and its molecular weight\
Fumaric acid is incorporated in the matrix tablet to maintain a pH-independent drug release across the intestinal pH rangeMultiparticulate capsule (MP)Formulated with coated pellets, wherein the drug is contained in the pellet core\
Release rate of omecamtiv mecarbil from the pellets is modulated by two successively applied functional coatings that also provide minimal pH dependence of the release across the intestinal pH rangeSwellable core tablets (SCT-F~1~, SCT-F~2~)Consist of bilayer core tablets, film-coated with an insoluble, semipermeable membrane\
A laser-drilled hole on the drug layer side enables osmotic-based drug release\
Composition is the same for both formulations\
Rate control is achieved by altering the ratio of insoluble polymer and water-soluble plasticizer in the semipermeable coating

![The effect of pH on the dissolution rates of 5 modified-release formulations of omecamtiv mecarbil. Normalized to 100% based on assay. MP = multiparticulate capsule; MRT-F = matrix tablet; SCT-F = swellable core tablet.](intjclinpharmacol-54-217-02){#Figure2}

Table 3.Baseline demographics.DemographicsSubjects (n = 65)Age, years  Mean (SD)33.0 (8.8)  Range18 -- 50Female, n (%)10 (15.4)Race, n (%)  White47 (72.3)  Black or African American17 (26.2)  Native Hawaiian or Pacific Islander1 (1.5)Hispanic or Latino ethnicity, n (%)35 (53.8)

Table 4.Pharmacokinetic parameters of OM following administration of 6 formulations in the fasting state.Pharmacokinetic parameterIR (n = 20)MRT-F~1~ (n = 21)MRT-F~2~ (n = 20)MP (n = 19)SCT-F~1~(n = 21)SCT-F~2~ (n = 21)OM  AUC~last~ (h×ng/mL)2,390 (385)2,030 (432)2,080 (623)1,520 (284)1,390 (489)1,970 (436)  AUC~∞~ (h×ng/mL)2,490 (432)2,150 (489)2,170 (663)1,590 (310)1,470 (541)2,060 (483)  C~max~ (ng/mL)262 (81)60 (17)78 (23)61 (21)34 (10)62 (16)  t~max~ (h)^a^0.5 (0.5 -- 1.0)3.0 (1.0 -- 12.0)2.0 (1.0 -- 10.0)4.0 (1.0 -- 6.0)10.0 (4.0 -- 25.0)\*6.0 (2.0 -- 10.0)\*  CL/F (L/h)10.3 (1.7)12.3 (3.0)12.5 (3.7)16.4 (4.3)19.2 (6.5)12.9 (3.4)  t~1/2,z~ (h)19.6 (4.2)21.4 (3.4)18.5 (4.8)20.0 (4.4)19.7 (4.4)20.5 (3.8)  F~rel~ to IR (AUC~∞~)^b^--0.79 (0.72 -- 0.86)0.87 (0.80 -- 0.95)0.64 (0.58 -- 0.70)0.58 (0.53 -- 0.63)0.82 (0.75 -- 0.90)M3  C~max~ (ng/mL)7.5 (2.2)3.9 (1.1)5.1 (1.5)4.7 (3.4)2.5 (0.8)4.2 (1.1)  AUC~last~ (h×ng/mL)217 (53)186 (61)196 (61)144 (40)120 (55)185 (36)  M3:OM AUC~last~ (h×ng/mL)9.1 (1.8)9.1 (2.3)9.7 (2.4)9.5 (2.1)8.5 (2.1)9.7 (2.0)M4  C~max~ (ng/mL)2.4 (0.9)1.6 (0.6)1.7 (0.8)1.4 (0.6)1.0 (0.3)1.6 (0.7)  AUC~last~ (h×ng/mL)70.7 (37.8)65.6 (35.6)57.7 (36.6)43.4 (28.6)32.6 (21.4)61.0 (35.1)  M4:OM AUC~last~ (h×ng/mL)3.0 (1.6)3.1 (1.4)2.7 (1.5)2.7 (1.8)2.1 (1.2)3.1 (1.6)[^2]

![Mean plasma concentration-time profiles of 6 formulations of omecamtiv mecarbil in the (A) fasting and (B) fed states. IR = immediate release; MP = multiparticulate capsule; MRT-F = matrix tablet; SCT-F = swellable core tablet.](intjclinpharmacol-54-217-03){#Figure3}

Table 5.Pharmacokinetic parameters of OM following administration of 6 OM formulations in the fed state.Pharmacokinetic parameterIR (n = 21)MRT-F~1~ (n = 20)MRT-F~2~ (n = 20)MP (n = 21)SCT-F~1~(n = 22)SCT-F~2~ (n = 22)OM  AUC~last~ (h×ng/mL)2,380 (433)2,420 (390)2,290 (520)1,620 (440)1,740 (492)2,070 (329)  AUC~∞~ (h×ng/mL)2,470 (464)2,540 (433)2,370 (582)1,690 (462)1,820 (529)2,150 (362)  C~max~ (ng/mL)144 (39)70 (16)90 (20)50 (13)51 (15)79 (14)  t~max~ (h)^a^2.0 (1.0 -- 8.0)6.0 (3.0 -- 12.0)4.0 (2.0 -- 8.0)8.0 (3.0 -- 10.0)10.0 (4.0 -- 12.0)6.0 (2.0 -- 8.0)  CL/F (L/h)10.5 (2.0)10.1 (1.8)11.1 (2.7)15.9 (4.6)14.8 (4.3)12.0 (2.5)  t~1/2,z~ (h)20.2 (3.6)20.6 (3.6)18.4 (4.6)19.0 (5.0)19.0 (3.9)19.5 (3.2)M3  C~max~ (ng/mL)6.7 (3.0)4.6 (1.6)5.7 (1.6)3.5 (1.4)3.5 (1.5)5.0 (1.2)  AUC~last~ (h×ng/mL)216 (60)216 (66)216 (59)146 (52)155 (59)198 (42)  M3:OM AUC~last~ (h×ng/mL)9.2 (2.6)9.0 (2.5)9.6 (2.1)9.1 (2.4)8.9 (2.1)9.7 (1.8)M4  C~max~ (ng/mL)2.0 (0.7)1.9 (0.8)1.9 (0.9)1.3 (0.6)1.4 (0.5)1.8 (0.6)  AUC~last~ (h×ng/mL)69.2 (38.7)79.7 (37.7)59.2 (39.6)40.4 (30.2)46.6 (27.6)62.8 (27.6)  M4:OM AUC~last~ (h×ng/mL)2.9 (1.6)3.3 (1.5)2.5 (1.6)2.4 (1.6)2.6 (1.3)3.0 (1.2)[^3]

![Mean M3 plasma concentration-time profiles of 6 omecamtiv mecarbil formulations in the (A) fasting and (B) fed states. IR = immediate release; MP = multiparticulate capsule; MRT-F = matrix tablet; SCT-F = swellable core tablet.](intjclinpharmacol-54-217-04){#Figure4}

![Mean M4 plasma concentration-time profiles of 6 omecamtiv mecarbil formulations in the (A) fasting and (B) fed states. IR = immediate release; MP = multiparticulate capsule; MRT-F = matrix tablet; SCT-F = swellable core tablet.](intjclinpharmacol-54-217-05){#Figure5}

Table 6.The food effect on the pharmacokinetic parameters of omecamtiv mecarbil following administration of 6 formulations.IRMRT-F~1~MRT-F~2~MPSCT-F~1~SCT-F~2~Fasting\
(n = 20)Fed\
(n = 21)Fasting\
(n = 21)Fed\
(n = 20)Fasting\
(n = 20)Fed\
(n = 20)Fasting\
(n = 19)Fed\
(n = 21)Fasting\
(n = 21)Fed\
(n = 22)Fasting\
(n = 21)Fed\
(n = 22)AUC~last~ LSGM2,3722,3511,8552,2562,0972,3431,4921,5711,3311,7191,9502,094NF/fasting (90% CI)0.99 (0.93 -- 1.05)1.22 (1.14 -- 1.29)1.12 (1.05 -- 1.19)1.05 (0.99 -- 1.12)1.29 (1.22 -- 1.37)1.07 (1.01 -- 1.14)AUC~∞~ LSGM2,4732,4471,9372,3462,1912,4221,5641,6481,4001,8072,0242,169Fed/fasting (90% CI)0.99 (0.93 -- 1.05)1.21 (1.14 -- 1.29)1.11 (1.04 -- 1.17)1.05 (0.99 -- 1.12)1.29 (1.22 -- 1.37)1.07 (1.01 -- 1.14)C~max~ LSGM25313955.165.576.888.957.848.333.150.162.381.1Fed/fasting (90% CI)0.55 (0.49 -- 0.62)1.19 (1.06 -- 1.33)1.16 (1.03 -- 1.29)0.84 (0.75 -- 0.94)1.51 (1.36 -- 1.69)1.30 (1.17 -- 1.45)t~max~0.52.03.06.02.04.04.08.010.010.06.06.0Median p-value^a^\< 0.00010.01840.01160.00020.05220.3173[^4]

Table 7.Treatment-emergent adverse events.IRMRT-F~1~MRT-F~2~MPSCT-F~1~SCT-F~2~Fasting, n (%)202120192121All adverse events2 (25.0)4 (19.0)5 (25.0)4 (21.1)2 (9.5)2 (9.5)Serious adverse events0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Fatal0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Leading to discontinuation1 (5.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Most common^a^  Headache2 (10.0)1 (4.8)1 (5.0)2 (10.5)1 (4.8)0 (0.0)  Vomiting0 (0.0)0 (0.0)1 (5.0)1 (5.3)1 (4.8)0 (0.0)  Nonfasting, n (%)212020212222  All adverse events5 (23.8)4 (20.0)1 (5.0)1 (4.8)4 (18.2)2 (9.1)  Serious adverse events0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)  Fatal0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)  Leading to discontinuation0 (0.0)0 (0.0)0 (0.0)1 (4.8)0 (0.0)0 (0.0)Most common^a^  Headache3 (14.3)1 (5.0)0 (0.0)0 (0.0)1 (4.5)1 (4.5)  Dermatitis contact0 (0.0)1 (5.0)1 (5.0)0 (0.0)0 (0.0)0 (0.0)  Upper respiratory tract infection1 (4.8)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (4.5)[^5]

[^1]: IR = immediate release; MP = multiparticulate; MRT-F = matrix tablet; SCT-F = swellable core tablet.

[^2]: Data presented as mean (SD) unless otherwise specified. AUC = area under the curve; AUC~∞~ = AUC to infinity; AUC~last~ = AUC to the time of last measureable concentration; CI = confidence interval; CL/F = clearance; C~max~ = maximum plasma concentration; F~rel~ = relative bioavailability; IR = immediate release; MP = multiparticulate; MRT-F = matrix tablet; OM = omecamtiv mecarbil; SCT-F = swallowable core tablet; t~max~ = time to reach C~max~; t~1/2z~ = half-life; t~max~ = time to reach C~max~. \*p \< 0.046 vs. IR; analyzed using a mixed-effect model, with treatment, study period, and sequence as fixed effects, and subject with in each sequence as a random effect. ^a^median (min -- max); ^b^geometric mean (90% CI).

[^3]: Data presented as mean (SD) unless otherwise specified. AUC = area under the curve; AUC~∞~ = AUC to infinity; AUC~last~ = AUC to the time of last measureable concentration; CL/F = clearance; C~max~ = maximum plasma concentration; IR = immediate release; MP = multiparticulate; MRT-F = matrix tablet; OM = omecamtiv mecarbil; SCT-F = swellable core tablet; t~1/2z~ = half-life; t~max~ = time to reach C~max~. ^a^median (min--max).

[^4]: AUC = area under the curve; AUC~∞~ = AUC to infinity; AUC~last~ = AUC to the time of last measureable concentration; CI = confidence interval; C~max~ = maximum plasma concentration; IR = immediate-release tablet; LSGM = least squares geometric mean; MP = multiparticulate; MRT-F = matrix tablet; NF = nonfasting; SCT-F = swallowable core tablet; t~max~ = time to reach C~max~. ^a^p value represents the difference in medians between fasting and nonfasting.

[^5]: IR = immediate release; MP = multiparticulate; MRT-F = matrix tablet; SCT-F = swellable core tablet. ^a^Occurring in ≥ 2 patients.
